Loading...
XKRX016580
Market cap127mUSD
Jan 08, Last price  
12,210.00KRW
1D
1.41%
1Q
-8.68%
Jan 2017
-22.97%
Name

Whanin Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:016580 chart
P/E
6.26
P/S
0.81
EPS
1,950.23
Div Yield, %
2.46%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
8.30%
Revenues
230.39b
+15.81%
80,091,447,00092,915,021,00099,386,536,000105,687,139,000110,052,051,320107,221,597,940104,479,910,140120,713,386,090145,397,202,330141,376,271,500147,953,429,460154,664,330,710159,176,971,650171,705,404,970177,775,700,610198,934,734,390230,393,578,986
Net income
29.77b
+24.47%
11,275,625,00011,154,237,00014,434,550,00017,236,908,00014,612,077,20015,796,562,80014,580,149,40018,805,535,45020,509,660,82016,397,455,15027,172,311,17021,517,959,15018,695,949,84023,387,790,17026,659,600,06023,921,351,11029,774,322,160
CFO
23.20b
+37.66%
9,578,987,0003,094,032,00018,607,208,00014,538,986,00015,115,299,99021,111,224,30010,666,757,40013,410,382,49015,927,221,68019,824,042,53023,479,839,41017,454,809,81024,730,950,63022,754,682,62035,317,945,23016,851,173,85023,196,782,380
Dividend
Dec 27, 2023300 KRW/sh
Earnings
Feb 12, 2025

Profile

Whan In Pharm Co.,Ltd., a pharmaceutical company, develops, manufactures, markets, and sells therapeutic products in South Korea. It offers anti-depressants, anti-psychotics, nootropics and anti-dementia, anti-epileptics, cardiovascular, gastrointestinal, antibiotics, antiviral agents, antihistamines, anti-inflammatory and analgesics, metabolic disorders, respiratory, central nervous system, other drug products. The company was founded in 1978 and is headquartered in Seoul, South Korea.
URL
https://www.whanin.com/
IPO date
Jul 03, 1996
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
230,393,579
15.81%
198,934,734
11.90%
Cost of revenue
169,758,727
138,763,813
Unusual Expense (Income)
NOPBT
60,634,852
60,170,922
NOPBT Margin
26.32%
30.25%
Operating Taxes
4,018,990
6,074,577
Tax Rate
6.63%
10.10%
NOPAT
56,615,862
54,096,344
Net income
29,774,322
24.47%
23,921,351
-10.27%
Dividends
(4,580,121)
(4,580,121)
Dividend yield
1.99%
1.70%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
324,969
186,323
Long-term debt
939,082
313,556
Deferred revenue
Other long-term liabilities
2,684,346
3,264,002
Net debt
(129,466,086)
(61,613,913)
Cash flow
Cash from operating activities
23,196,782
16,851,174
CAPEX
(30,530,920)
(67,758,978)
Cash from investing activities
(9,431,669)
(38,942,000)
Cash from financing activities
(5,166,024)
(5,130,104)
FCF
17,200,188
(21,488,223)
Balance
Cash
78,457,021
87,291,911
Long term investments
52,273,116
(25,178,119)
Excess cash
119,210,458
52,167,055
Stockholders' equity
349,684,222
612,234,421
Invested Capital
242,313,394
280,137,317
ROIC
21.67%
21.15%
ROCE
16.77%
18.09%
EV
Common stock shares outstanding
15,267
15,267
Price
15,040.00
-14.55%
17,600.00
-1.12%
Market cap
229,616,733
-14.55%
268,700,432
-1.12%
EV
100,150,647
207,503,270
EBITDA
67,294,242
65,017,676
EV/EBITDA
1.49
3.19
Interest
22,656
51,876
Interest/NOPBT
0.04%
0.09%